Skip to main content

Bruker to Pay $2.4M to Settle SEC Violations Related to China Business

NEW YORK (GenomeWeb) — The US Securities and Exchange Commission today charged Bruker with violating the Foreign Corrupt Practices Act.

The SEC charged that the Billerica, Mass.-based company provided non-business related travel and improper payments to Chinese government officials in an effort to win business.

Bruker has agreed to pay approximately $2.4 million to settle the charges, including $1,714,852 in disgorgement, $310,117 in prejudgment interest, and a $375,000 penalty.

An investigation by the agency found that Bruker lacked sufficient internal controls to prevent and detect roughly $230,000 in improper payments made out of its China-based offices. According to the SEC, the company's China-based offices falsely recorded these payments in their records as legitimate business and marketing expenses.

Bruker realized roughly $1.7 million in profits from sales contracts with state-owned entities in China whose officials received the improper payments, the SEC said. It added that Bruker self-reported the misconduct and provided "extensive cooperation" during the SEC's investigation. 

The company has consented to the order without admitting or denying the SEC findings.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.